- Conditions
- Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, GastroEsophageal Cancer, Head and Neck Cancer, Hepatocellular Cancer, Non-small Cell Lung Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Renal Cancer, Thyroid Cancer, Urothelial Carcinoma (UC), Cholangiocarcinoma, Mesothelioma, Gallbladder Cancer, Ovarian Cancer
- Interventions
- MDX2001
- Drug
- Lead sponsor
- ModeX Therapeutics, An OPKO Health Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 6
- States / cities
- Denver, Colorado • Miami, Florida • Boston, Massachusetts + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2473–2496
of 4,500
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer, Hypercalcemia of Malignancy, Colon Cancer, Endocrine Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Lymphoma, Metastatic Cancer, Multiple Myeloma, Parathyroid Neoplasms, Renal Cancer, Thyroid Cancer, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Non-Small Cell Lung Cancer
- Interventions
- denosumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 12
- States / cities
- Encinitas, California • New Haven, Connecticut • Salisbury, Maryland + 9 more
- Conditions
- Pulmonary Neoplasms
- Interventions
- Radiofrequency Ablation of pulmonary neoplasms
- Procedure
- Lead sponsor
- Oncology Specialties, Alabama
- Other
- Eligibility
- 19 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Huntsville, Alabama
- Conditions
- Oncology, Melanoma, Ovarian Cancer, NSCLC, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Cancer, CRC, Colon Cancer, Breast Cancer, Gastric Cancer, EGJ, Esophagogastric Junction Cancer, Head and Neck Cancer, Urothelial Cancer, Bladder Cancer
- Interventions
- E-602, Cemiplimab
- Biological
- Lead sponsor
- Palleon Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 13
- States / cities
- La Jolla, California • Los Angeles, California • Stanford, California + 10 more
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- iSABR, 25 Gray in 1 fraction for small peripheral tumors, iSABR, 50 Gray in 4 fractions for medium peripheral tumors, iSABR, 54 Gray in 3 fractions for large peripheral tumors, iSABR, 40 Gray in 4 fractions for small central tumors, iSABR, 50 Gray in 4 fractions for medium central tumors, iSABR, 60 Gray in 8 fractions for large central tumors
- Radiation
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2022
- U.S. locations
- 2
- States / cities
- Stanford, California • Seattle, Washington
- Conditions
- Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Interventions
- Biospecimen Collection, Lumbar Puncture, Magnetic Resonance Imaging
- Procedure · Device
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Cancer
- Interventions
- capecitabine, cisplatin
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Smoking, Lung Cancer
- Interventions
- Telephone Counseling, Minimal Treatment
- Behavioral
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Burlington, Massachusetts • Hackensack, New Jersey
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- PR610
- Drug
- Lead sponsor
- Proacta, Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Sacramento, California • Chicago, Illinois + 1 more
- Conditions
- HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification
- Interventions
- ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Trastuzumab emtansine
- Drug
- Lead sponsor
- Enliven Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Orlando, Florida • Plantation, Florida + 2 more
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Interventions
- Azacitidine, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Amivantamab, Lazertinib, Carboplatin, Pemetrexed
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 6
- States / cities
- Duarte, California • Irvine, California • Stanford, California + 2 more
- Conditions
- Lung Cancer, Non-Small Cell Lung Cancer
- Interventions
- BMS-986205, Nivolumab, Chemotherapy
- Drug · Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 19
- States / cities
- San Diego, California • Fort Myers, Florida • Jacksonville, Florida + 16 more
- Conditions
- Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer, Colorectal Cancer, Lung Adenocarcinoma, Renal Cell Carcinoma, Triple Negative Breast Cancer, Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer, Ovarian Cancer
- Interventions
- PY314, Combination Therapy: PY314 + Pembrolizumab
- Drug
- Lead sponsor
- Ikena Oncology
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 18 more
- Conditions
- Carcinoma, Non-Small Cell Lung
- Interventions
- Rilvegostomig, Pembrolizumab
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 830 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 39
- States / cities
- La Mesa, California • Los Alamitos, California • Newark, Delaware + 36 more
- Conditions
- Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors, HER2-positive Metastatic Breast Cancer, KRAS Mutant Metastatic Colorectal Cancer, Metastatic Lung Cancer, Metastatic Colorectal Cancer, Advanced Lung Cancer, HR-positive, HER2-negative Advanced Breast Cancer, HER2-positive Advanced Breast Cancer
- Interventions
- BBO-10203, Trastuzumab, Fulvestrant, Ribociclib, FOLFOX, Bevacizumab
- Drug
- Lead sponsor
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 392 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 19
- States / cities
- Duarte, California • Los Angeles, California • San Diego, California + 13 more
- Conditions
- Carcinoma, Non-Small-Cell Lung Carcinoma, Head and Neck Neoplasms
- Interventions
- AZD2171
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lung Cancer
- Interventions
- vinorelbine tartrate
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2007
- U.S. locations
- 13
- States / cities
- Scottsdale, Arizona • Urbana, Illinois • Cedar Rapids, Iowa + 10 more
- Conditions
- Non-Small Cell Lung Cancer, Lung Cancer
- Interventions
- Erlotinib, Carboplatin, Paclitaxel, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Custirsen, Docetaxel
- Drug
- Lead sponsor
- Achieve Life Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 664 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 14
- States / cities
- Boynton Beach, Florida • Orlando, Florida • Athens, Georgia + 10 more
- Conditions
- ALK-positive Advanced NSCLC
- Interventions
- Crizotinib, Pembrolizumab
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Duarte, California • La Jolla, California + 4 more
- Conditions
- HER2-expressing Cancers
- Interventions
- ZW49
- Drug
- Lead sponsor
- Zymeworks BC Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 8
- States / cities
- Duarte, California • Tampa, Florida • Chicago, Illinois + 5 more
- Conditions
- Lung Cancer
- Interventions
- biricodar dicitrate, doxorubicin hydrochloride, vincristine sulfate
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 9
- States / cities
- Little Rock, Arkansas • Indianapolis, Indiana • Boston, Massachusetts + 5 more
- Conditions
- Pleural Effusions
- Interventions
- Not listed
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 625 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Tucson, Arizona